4 recruiting, 1 withdrawn. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 4, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Locally Advanced Triple-Negative Breast Carcinoma: new trials by email Literature Review of Locally Advanced Triple-Negative Breast Carcinoma trials Research Report on Locally Advanced Triple-Negative Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer Ipilimumab, Pembrolizumab, Vaccine Therapy - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Recruiting | Emory University | 18 | 2025-12-02 | 2026-01-26 |
| Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2025-08-04 | 2025-07-03 | |
| A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer Pembrolizumab, Cryoablation, Histotripsy - Metastatic Breast Cancer, Breast Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2024-01-29 | 2026-09-14 |
| Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 57 | 2023-05-18 | 2026-09-30 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
Triple Negative Breast Neoplasms (5) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
Breast Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Breast Neoplasms (3) · Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Squamous Cell (1) · DNA Virus Infections (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1)
pembrolizumab (4) · Biopsy (3) · Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · X-Rays (2) · 130-nm albumin-bound paclitaxel (1) · ASTX-660 (1) · Albumin-Bound Paclitaxel (1) · CTLA-4 Antigen (1) · Colony-Stimulating Factors (1) · Cryosurgery (1) · Cyclophosphamide (1) · Immunoglobulin G (1) · Immunotherapy, Active (1) · Ipilimumab (1)
National Cancer Institute (NCI) (2) · Emory University (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1)
United States (4)
Ana C Garrido-Castro (1) · Keerthi Gogineni, MD, MSHP (1) · Kristen Kelley (1) · Yanyan Lou, MD, PhD (1) · Yolanda Bryce, MD (1)
P30CA138292 (1), R44CA257278 (1), UM1CA186709 (1), UM1CA186712 (1)